Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting
April 25, 2022 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that two abstracts have been accepted for poster...
Vor Bio Announces Retirement of Chief Medical Officer
April 14, 2022 16:15 ET
|
Vor Biopharma
CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Christopher Slapak, Chief Medical Officer...
Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
March 14, 2022 16:30 ET
|
Vor Biopharma
Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022New program VCAR33ALLO using healthy donor-derived T cells IND submission expected in 1H 2023Cash runway extended...
Vor to Participate in Three Upcoming Investor Conferences
February 28, 2022 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will...
Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 11, 2022 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief...
Vor to Participate in Two Upcoming Investor Conferences
January 04, 2022 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will...
Vor to Participate in the JMP Securities Hematology and Oncology Summit
November 29, 2021 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief...
Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference
November 19, 2021 16:01 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief...
Vor Reports Third Quarter 2021 Financial Results and Provides Company Update
November 10, 2021 16:10 ET
|
Vor Biopharma
VOR33 on track with initial clinical data expected in the first half of 2022Announced pipeline expansion with first multi-targeted Treatment System simultaneously targeting CD33 and CLL-1 for AML ...
Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting
November 09, 2021 08:30 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of new data from its novel...